Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies, Inc. SEC filings document the public-company record for a biotechnology diagnostics issuer with Nasdaq-listed common stock and tradeable warrants. The filings identify the company as an emerging growth company and smaller reporting company and include disclosures tied to CyPath® Lung, laboratory services, operating performance, and securities registration activity.
Recent filings include Form 8-K reports for financial results, Regulation FD presentation materials, product and clinical-case announcements, and annual meeting voting results. The record also covers governance matters such as director elections and equity incentive plan amendments, along with S-1 registration materials describing securities being registered and related issuer classifications.
bioAffinity Technologies, Inc. completed a best efforts public offering of 4,000,000 securities, consisting of 1,040,000 shares of common stock and pre-funded warrants to purchase up to 2,960,000 shares, at $0.80 per share or $0.793 per pre-funded warrant, generating gross proceeds of about $3.2 million before fees.
Each pre-funded warrant is immediately exercisable for one share at an exercise price of $0.007 and remains exercisable until used, subject to a 4.99% (or 9.99% at the holder’s election) beneficial ownership cap. The company agreed to 30-day restrictions on additional equity issuances and at-the-market offerings, broader limits on variable rate transactions for three months, and 30-day lock-ups for executives and directors. After the offering, 6,283,061 shares of common stock are outstanding, and proceeds are earmarked for working capital and general corporate purposes.
bioAffinity Technologies, Inc. completed a best efforts public offering of 4,000,000 securities, consisting of 1,040,000 shares of common stock and pre-funded warrants to purchase up to 2,960,000 shares, at $0.80 per share or $0.793 per pre-funded warrant, generating gross proceeds of about $3.2 million before fees.
Each pre-funded warrant is immediately exercisable for one share at an exercise price of $0.007 and remains exercisable until used, subject to a 4.99% (or 9.99% at the holder’s election) beneficial ownership cap. The company agreed to 30-day restrictions on additional equity issuances and at-the-market offerings, broader limits on variable rate transactions for three months, and 30-day lock-ups for executives and directors. After the offering, 6,283,061 shares of common stock are outstanding, and proceeds are earmarked for working capital and general corporate purposes.
bioAffinity Technologies is offering 1,040,000 shares of common stock at $0.80 per share and registering up to 2,960,000 pre-funded warrants exercisable at $0.007 to prevent purchasers exceeding 4.99% (or 9.99% by election) ownership. The prospectus states estimated net proceeds of approximately $2.6 million and a Placement Agent fee of 7.5%.
The offering includes Placement Agent Warrants equal to 3.0% of shares sold at an exercise price of $0.88. Shares outstanding were 4,743,061 as of June 16, 2026, and would be 8,743,061 assuming full exercise of pre-funded warrants sold hereunder.
bioAffinity Technologies is offering 1,040,000 shares of common stock at $0.80 per share and registering up to 2,960,000 pre-funded warrants exercisable at $0.007 to prevent purchasers exceeding 4.99% (or 9.99% by election) ownership. The prospectus states estimated net proceeds of approximately $2.6 million and a Placement Agent fee of 7.5%.
The offering includes Placement Agent Warrants equal to 3.0% of shares sold at an exercise price of $0.88. Shares outstanding were 4,743,061 as of June 16, 2026, and would be 8,743,061 assuming full exercise of pre-funded warrants sold hereunder.
bioAffinity Technologies filed Amendment No. 1 to its Registration Statement on Form S-1. The amendment is narrowly focused and is being used to add specific deal-related documents as exhibits, rather than to change the overall terms of the planned offering.
The company is filing the form of Placement Agency Agreement with WallachBeth Capital LLC, along with the form of Pre-Funded Warrant and the form of Placement Agent Warrant, as new exhibits. The rest of the S-1 remains unchanged and is incorporated by reference. The amendment also restates standard undertakings on indemnification of directors and officers and includes updated signature pages from the company’s chief executive officer, chief financial officer, and directors.
bioAffinity Technologies filed an update describing an educational webinar on July 21, 2026, focused on lung health screening and early detection for U.S. veterans at increased risk for lung cancer and other respiratory diseases. The session will cover imaging, noninvasive diagnostics and access to screening and follow-up care.
The webinar is hosted by NAVREF and will feature experts from Philips, bioAffinity Technologies and 4DMedical. Speakers will discuss mobile CT screening, CyPath® Lung testing and advanced functional lung imaging as approaches that may help support earlier detection and clinical decision-making in veteran populations.
The filing also highlights CyPath® Lung, a noninvasive sputum-based test for high-risk patients, which in a published clinical trial showed 92% sensitivity, 87% specificity, 88% accuracy and a 99% negative predictive value for detecting lung cancer in patients with small indeterminate nodules.
bioAffinity Technologies, Inc. is conducting a primary offering of 2,631,579 shares of common stock, together with pre-funded and placement agent warrants and the shares issuable upon their exercise. The assumed price is $1.52 per share, implying estimated net proceeds of about $3.4 million for working capital and general corporate purposes.
The company focuses on noninvasive lung diagnostics, led by its CyPath® Lung test, which showed 92% sensitivity, 87% specificity, and 88% accuracy for small pulmonary nodules in a clinical trial. CyPath® Lung unit sales grew 146% year over year in first-quarter 2026, and a new multicenter clinical trial began enrolling in March 2026.
bioAffinity reported $1.4 million in revenue for the quarter ended March 31, 2026, and $6.2 million and $9.4 million in 2025 and 2024, respectively, but had an accumulated deficit of $72.2 million and $3.1 million in cash. Its auditor raised substantial doubt about its ability to continue as a going concern, and management indicates existing cash supports operations only through June 2026 without additional financing.
bioAffinity Technologies, Inc. filed an 8-K to share a press release about an educational webinar hosted by the Society for Advanced Bronchoscopy on CyPath® Lung’s role in detecting and managing early-stage lung cancer. The live event, titled “Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath® Lung Testing,” is scheduled for Tuesday, June 16, at 7 p.m. ET.
The press release explains that CyPath® Lung is a noninvasive sputum test using advanced flow cytometry, a fluorescent porphyrin, and proprietary artificial intelligence to analyze the lung microenvironment. In a published clinical trial of high-risk patients with small indeterminate lung nodules less than 20 millimeters, CyPath® Lung showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in detecting lung cancer. The company notes that the test is marketed as a Laboratory Developed Test under CLIA oversight and is intended to be used alongside other clinical findings rather than as a standalone diagnostic.
bioAffinity Technologies, Inc. reported that it received a notification of allowance from the Mexican Institute of Industrial Property for a patent covering methods of predicting the likelihood of lung cancer using flow cytometry. The patent will protect use of specific antibodies, the porphyrin TCPP, and flow cytometry to detect cancer cells in sputum for the company’s CyPath® Lung test.
CyPath® Lung is a noninvasive, at-home sputum-based test for high-risk patients that uses advanced flow cytometry and artificial intelligence. In a published clinical trial of high-risk patients with small indeterminate lung nodules, CyPath® Lung showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in detecting lung cancer.
bioAffinity Technologies, Inc. is registering 497,483 shares of Common Stock for resale by selling stockholders pursuant to this prospectus. The shares comprise 365,603 Warrant Shares issuable upon anti-dilution adjustments to outstanding warrants and 131,880 Conversion Shares issuable upon anti-dilution adjustments to Series B Convertible Preferred Stock.
The company is not offering any shares for its own account and will not receive proceeds from resales by the selling stockholders; the company would receive cash only if the related Warrants are exercised for cash. Share counts in this prospectus assume conversion/exercise for resale purposes and state 4,498,675 shares outstanding as of December 31, 2025, rising to 4,996,155 shares after the offering per the offering table.